acetoacetic acid has been researched along with Weight Reduction in 4 studies
acetoacetic acid : A 3-oxo monocarboxylic acid that is butyric acid bearing a 3-oxo substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three clinical studies were conducted: a bariatric surgery cohort study of participants with morbid obesity who underwent either Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) studied over four and twelve weeks, and two randomized placebo-controlled, crossover double blind studies of liraglutide vs." | 5.69 | Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. ( Alexandrou, A; Angelidi, AM; Connelly, MA; Kokkinos, A; Mantzoros, CS; Mingrone, G; Sanoudou, D, 2023) |
| "Unified Parkinson's Disease Rating Scale scores improved in all five during hyperketonemia, but a placebo effect was not ruled out." | 2.71 | Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. ( Boyar, K; Di Rocco, A; Heymsfield, SB; Hyams, K; Nonas, C; Vanitallie, TB, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spigoni, V | 1 |
| Cinquegrani, G | 1 |
| Iannozzi, NT | 1 |
| Frigeri, G | 1 |
| Maggiolo, G | 1 |
| Maggi, M | 1 |
| Parello, V | 1 |
| Dei Cas, A | 1 |
| Angelidi, AM | 1 |
| Kokkinos, A | 1 |
| Sanoudou, D | 1 |
| Connelly, MA | 1 |
| Alexandrou, A | 1 |
| Mingrone, G | 1 |
| Mantzoros, CS | 1 |
| Aksungar, FB | 1 |
| Sarıkaya, M | 1 |
| Coskun, A | 1 |
| Serteser, M | 1 |
| Unsal, I | 1 |
| Vanitallie, TB | 1 |
| Nonas, C | 1 |
| Di Rocco, A | 1 |
| Boyar, K | 1 |
| Hyams, K | 1 |
| Heymsfield, SB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Study of the Effects of Roux en Y Gastric Bypass and Sleeve Gastrectomy on Postprandial Gut Hormone Responses, Glycemia and Lipid Profile, Weight Loss, and Indices of Cardiovascular Risk[NCT03851874] | 28 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI[NCT01562678] | Phase 4 | 28 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Saxenda: Underlying Mechanisms and Clinical Outcomes[NCT02944500] | Phase 4 | 28 participants (Actual) | Interventional | 2016-11-30 | Active, not recruiting | ||
| Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome[NCT05469997] | 50 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | |||
| Effect of a Lipidic and Proteic Controlled Diet on Resting Energy Expenditure, Body Composition and Symptoms in Patients With Parkinson's Disease[NCT02687698] | 36 participants (Anticipated) | Interventional | 2016-02-29 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Effect size (region of interest z-scores, derived from z-maps of the brain) shown below is the difference in parietal cortex activation to highly desirable (high fat or high calorie, e.g. cakes, pies, fries) versus less desirable (low fat or low calorie, e.g. vegetables, fruits) food cues for each treatment condition (liraglutide or placebo) at the end of the treatment period. (NCT01562678)
Timeframe: 18 days of Liraglutide or placebo treatment
| Intervention | z-scores of activation in cortex (Mean) |
|---|---|
| Liraglutide | -0.42 |
| Placebo | 0.53 |
1 review available for acetoacetic acid and Weight Reduction
| Article | Year |
|---|---|
Activation of G protein-coupled receptors by ketone bodies: Clinical implication of the ketogenic diet in metabolic disorders.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Carbohydrates; Diet, Ketogenic; Humans; Ketone Bodies; Ketones | 2022 |
2 trials available for acetoacetic acid and Weight Reduction
| Article | Year |
|---|---|
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
1 other study available for acetoacetic acid and Weight Reduction
| Article | Year |
|---|---|
Comparison of Intermittent Fasting Versus Caloric Restriction in Obese Subjects: A Two Year Follow-Up.
Topics: Acetoacetates; Adult; Blood Glucose; Body Mass Index; Caloric Restriction; Diet; Fasting; Female; Fo | 2017 |